Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ch related initiatives, including:

  • Significant management additions to U.S. commercial team: VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Market research updates to support launch planning and sales force sizing
  • Continued pursuit of our desired reimbursement scenarios for Qutenza

The Company expects to provide an update and additional details on U.S. commercialization plans once it learns the outcome of the FDA review of Qutenza in PHN.

In late September 2009, the Company completed the transfer of the Qutenza Marketing Authorization (MA) to Astellas, which is now the legal holder of the MA. In accordance with the licensing agreement between NeurogesX and Astellas, the MA transfer supports the E.U. launch of Qutenza for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. As a result of the MA transfer, Astellas is now responsible for ongoing maintenance of the MA, including certain post-marketing commitments for a safety and efficacy study of Qutenza.

In addition to Qutenza launch preparation activities, the Company appointed Bradford S. Goodwin to its Board of Directors as a director and Audit Committee chairman. Mr. Goodwin is currently President and CEO of Keren Pharmaceutical, nonexecutive chairman of Facet Biotech Corp. and a director of Rigel, Inc. He is a healthcare industry veteran that has held various senior executive positions at Novacea, Inc., Collabra Pharma, and Genentech, Inc.

Anthony DiTonno, President and CEO, commented, "The NeurogesX team continues to operate at exceptional levels as our focus remains squarely fixed on the upcoming PDUFA date for the potential U.S. approval of Qutenza in PHN. During the third quarter our commercialization readiness activities for Qutenza took center stage. Turning towards the E.U. launch, our highly collaborative and posit
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... Systems Inc.,(Amex: PLC ) today announced that it ... dated September 17, 2008 from the Listing,Qualifications Department staff ... Company was not in compliance with Section 1003(a)(ii) of,the ... less,than $4,000,000 as of June 30, 2008, and it ...
... 18 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a ... anti-adhesion, drug delivery products and other,surgical implants, announced ... the,AdvaMed 2008 MedTech conference being held in Washington, ... and CEO of SyntheMed, is scheduled,to present on ...
... NOVATO, Calif., Sept. 18 BioMarin,Pharmaceutical Inc. (Nasdaq: ... article released by Bloomberg this morning. The article ... Chief Executive Officer of,BioMarin, held on September 17, ... is consistent with the,information previously released publicly:, ...
Cached Biology Technology:PLC Systems Receives Delisting Notice From American Stock Exchange 2SyntheMed To Present at the AdvaMed 2008 MedTech Conference 2BioMarin Corrects Information Included in Bloomberg Article 2BioMarin Corrects Information Included in Bloomberg Article 3
(Date:4/23/2014)... A biomedical engineer at the University of Houston ... make blood transfusions safer. His work is supported by ... Health (NIH). , Blood transfusions save millions of ... absolute necessities. Without them, for instance, routine surgeries would ... however. There,s strong evidence that transfusions of red blood ...
(Date:4/22/2014)... secret to get your child to behave at the dinner ... Cornell study published in Eating Behaviors , found that ... bite with their front teeth such as drumsticks, whole apples, ... when these foods had been cut. "They were twice ... other kids," said Brian Wansink, Professor and Director of the ...
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... http://www.biologists.com/ ) organises and supports a themed conference as the ... of Experimental Biology . The main aim of this annual ... varied expertise on one particular subject. It is a leisurely ... social side of science is also catered for an ...
... survive chemotherapy leaving the door open to recurrence ... an original method for imaging and analyzing many thousands ... drug affects each one. For research student ... in the lab of Prof. Uri Alon of the ...
... The University of Nottingham have been involved in a scientific ... be more likely to suffer from the chronic skin condition, ... the journal Nature Genetics , shows that people who ... be affected by psoriasis. These two genes appear to be ...
Cached Biology News:Survival in a Changing World: The Journal of Experimental Biology 2009 symposium 2Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug 2Missing genes link to psoriasis 2
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Request Info...
GBL Antibody...
Dnase and Rnase free...
Biology Products: